Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study

Journal of Clinical Oncology

Volumn 18, Issue 2, 2000, Pages 371-375

  Stadler, Walter M ^a   Vogelzang, Nicholas J ^a   Amato, Robert ^a   Sosman, Jeffery ^a   Taber, David ^a   Liebowitz, David ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CANCER; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0033955395     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.2.371     Document Type: Article

References (21)

1. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
2. Kaur G, Stetler-Stevenson M, Sebers S, et al: Growth inhibition and reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84:1736-1740, 1992
3. Losiewicz MD, Carlson BA, Kaur G, et al: Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Comm 201:589-595, 1994
4. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharm 46:1831-1840, 1993
5. Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G1 arrest with inhibition of cyclin dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978, 1996
6. Arguello F, Alexander M, Sterry JA, et al: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490, 1998
7. Bible KC, Kaufmann SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861, 1996
8. Konig A, Schwartz GK, Mohammad RM, et al: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90:4307-4312, 1997
9. Parker BW, Kaur G, Nieves-Neira W, et al: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465, 1998
10. Patel V, Senderowicz AM, Pinto D Jr, et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 102:1674-1681, 1998
11. Chien M, Astumian M, Liebowitz D, et al: In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chem Pharm 44:81-87, 1999
12. Brusselbach S, Nettelbeck DM, Sedlacek HH, et al: Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. Int J Cancer 77:146-152, 1998
13. Kim WJ, Kakehi Y, Kinoshita H, et al: Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 156:506-511, 1996
14. Sedlacek HH, Czech J, Naik R, et al: Flavopiridol (L86-8275, NSC-649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143-1168, 1996
15. Drees M, Dengler W, Roth T, et al: Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 32:273-279, 1997
16. Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999, 1998
17. Thomas J, Cleary J, Tutsch K, et al: Phase I clinical and pharmacokinetic trial of flavopiridol. Proc Ann Meet Am Assoc Cancer Res 38:1997 (abstr A1496)
18. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
19. Schwartz GK, Farsi K, Maslak P, et al: Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells. Clin Cancer Res 3:1467-1472, 1997
20. Bible KC, Kaufmann SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res 57:3375-3380, 1997
21. Motzer R, Vogelzang NJ: Chemotherapy for renal cell carcinoma, in Raghavan D, Scher H, Leibel S, et al (eds): Principles and Practice of Genitourinary Oncology. Philadelphia, PA, Lippincott, 1997, pp 885-896